WISeKey selected by the German health tech company Digital Diagnostics AG to secure its digid cantisense™ SARS-CoV-2 test
WISeKey has been selected by Digital Diagnostics AG to secure its digid cantisense™ SARS-CoV-2 test. This revolutionary test allows for immediate on-site COVID-19 antigen testing, yielding results in five minutes. The partnership positions WISeKey to capitalize on the growing AIoT market in healthcare, projected to generate over $10 million in revenue in 2021. The integration of AI and IoT technologies enhances data processing and real-time monitoring capabilities, paving the way for innovative healthcare solutions.
- Partnership with Digital Diagnostics AG strengthens WISeKey's position in the healthcare sector.
- Projected revenue of over $10 million from AIoT healthcare initiatives in 2021.
- The cantisense™ test offers rapid results, enhancing testing accessibility and efficiency.
- None.
WISeKey selected by the German health tech company Digital Diagnostics AG to secure its digid cantisense™ SARS-CoV-2 test
Geneva – September 14, 2020 - WISeKey International Holding Ltd (“WISeKey”, SIX: WIHN / Nasdaq: WKEY), a leading cybersecurity and IoT company was selected by the German health tech company digid - Digital Diagnostics AG, to secure its digid cantisense™ SARS-CoV-2 test.
WISeKey cybersecurity and Identity Management is used to digitally certify and encrypt the data originated by a new type of sensor device from the German health tech company Digital Diagnostics AG that can be used for immediate tests for the new SARS coronavirus. The digid cantisense™ SARS-CoV-2 test becomes a pocket-sized laboratory and can be used in four steps anywhere on site by general practitioners, paramedics and nursing staff without much prior knowledge.
The new rapid test detects antigens of SARS CoV-2 directly. Compared to previously known rapid tests, it reacts much better and leads to a clear electronic “YES” or “NO” statement regarding the presence of the virus in the test liquid. The results are available within five minutes; the time-consuming transport of the samples to the laboratory is no longer necessary.
The new digital diagnostic platform enables the rapid testing of millions of people and thus enables real-time monitoring of the spread of the disease within the population. By connecting the digital sensor to a secure database, new regional hotspots of the virus spread can be recognized in real time and immediately contained.
“This new win reinforces the overarching objective for WISekey is to establish a foothold into the Artificial Intelligence of Things (“AIoT”) market for health sector. This new segment, projected to bring over
WISeKey’s medium term digital transformation strategy is to leverage its technology platform via long-lasting relationships with strategic partners designed to bring a stream of high-profile clients that are in high demand for cybersecurity solutions, such as AI, digital identity and privacy, secure mobile communication, secure cloud computing, IoT, secure semi-conductors, Blockchain and other innovative technologies offered by WISeKey. WISeKey AIoT technology resulting from the groundbreaking combination of their industry leading products: arago’s AI based Knowledge Automation and Data platform and WISeKey’s Cybersecurity and IoT technologies.
WISeAI integrates semiconductors, MEMS, smart sensors, IoT systems, Artificial Intelligence and a data cloud to deliver to customers a unique offering to power innovation and digital transformation. Using WISeKey’s cybersecurity technology and IoT network, data will be collected in HIRO where it can be processed and through automation acted upon in real time in a highly secure environment.
AIoT is the brain that will power the nervous system of the network of IoT objects operating in the WISeKey ecosystem, which currently connects over 1.6 billion IoT devices secured with WISeKey’s VaultIC. With the introduction of 5G, the ecosystem will continue to grow at a much faster rate as 5G will enable the connection of every object, person, and machine. AIoT will embed AI into the core infrastructure components of the ecosystem including Root of Trust, semiconductors, and edge computing. Specialized APIs are then used to provide interoperability between components at the device, software and platform level to optimize system and network operations. Data processed through AIoT is then collected and made accessible to extract value and enhance market intelligence and knowledge for customers. AIoT also enables secure automation of actions and business decisions based on real time data and enables IoT to work independently with minimal human support, unlike the current state of the market which requires that all actions be coded in advance based on pre-defined scenarios.
With the use of AI algorithms and predictive maintenance implemented through AIoT, IoT devices will have the capability to dynamically determine actions to take decisions, self-program based on analytics, and customer defined knowledge, resulting in lower operating and maintenance costs for providers.
Micro-Electro-Mechanical System (MEMS)
The Digital Diagnostics’ AG cantisense ™ SARS-CoV-2 test is based on cantilevers that are integrated into a sandcorn sized microchip. These nanomechanical cantilevers made of silicon are extremely thin and can be bent with just a tiny amount of force. This makes them highly sensitive biochemical sensors. In the digid cantisense ™ SARS-CoV-2 test, the cantilevers are coated with a trapping layer of antibodies. These antibodies bind the SARS CoV2 that are applied to the chip during the above described test process. When the new coronavirus binds to the trap layer, changes in surface tension lead to a mechanical bend that generates an electrical signal on the chip.
About Digital Diagnostics AG
Digital Diagnostics AG is a German health tech company currently developing a groundbreaking digital diagnostic platform based on the proprietary cantisense ™ biosensor technology and an ecosystem of mobile applications to enable AI-based real-time diagnostics of human and animal biodata.
Press Contact:
Thomas Huber
semanticom GmbH
+49 30 275 80 81 11
digid-pr@semanticom.eu
About ARAGO
ARAGO GmbH, Eschersheimer Landstraße 526, 60433 Frankfurt am Main (AG Frankfurt, HRB 100909) is a German technology private company which aim is to provide the benefits of Artificial Intelligence to enterprise customers globally through Knowledge Automation. Founded in Frankfurt am Main 1995 the company uses modern technologies such as inference and machine learning in order to automatically operate any business process.
About WISeKey:
WISeKey (NASDAQ: WKEY; SIX Swiss Exchange: WIHN) is a leading global cybersecurity company currently deploying large scale digital identity ecosystems for people and objects using Blockchain, AI and IoT respecting the Human as the Fulcrum of the Internet. WISeKey microprocessors secure the pervasive computing shaping today’s Internet of Everything. WISeKey IoT has an install base of over 1.5 billion microchips in virtually all IoT sectors (connected cars, smart cities, drones, agricultural sensors, anti-counterfeiting, smart lighting, servers, computers, mobile phones, crypto tokens etc.). WISeKey is uniquely positioned to be at the edge of IoT as our semiconductors produce a huge amount of Big Data that, when analyzed with Artificial Intelligence (AI), can help industrial applications to predict the failure of their equipment before it happens.
Our technology is Trusted by the OISTE/WISeKey’s Swiss based cryptographic Root of Trust (“RoT”) provides secure authentication and identification, in both physical and virtual environments, for the Internet of Things, Blockchain and Artificial Intelligence. The WISeKey RoT serves as a common trust anchor to ensure the integrity of online transactions among objects and between objects and people. For more information, visit www.wisekey.com.
Press and investor contacts:
| WISeKey International Holding Ltd Company Contact: Carlos Moreira Chairman & CEO Tel: +41 22 594 3000 info@wisekey.com | WISeKey Investor Relations (US) Contact: Lena Cati The Equity Group Inc. Tel: +1 212 836-9611 lcati@equityny.com |
Disclaimer:
This communication expressly or implicitly contains certain forward-looking statements concerning WISeKey International Holding Ltd and its business. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of WISeKey International Holding Ltd to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. WISeKey International Holding Ltd is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.
This press release does not constitute an offer to sell, or a solicitation of an offer to buy, any securities, and it does not constitute an offering prospectus within the meaning of the Swiss Financial Services Act (“FinSA”), the FInSa’s predecessor legislation or advertising within the meaning of the FinSA, or within the meaning of any other securities regulation. Investors must rely on their own evaluation of WISeKey and its securities, including the merits and risks involved. Nothing contained herein is, or shall be relied on as, a promise or representation as to the future performance of WISeKey.
The securities offered will not be, and have not been, registered under the United States of America Securities Act of 1933, as amended, and may not be offered or sold in the United States of America, absent registration or an applicable exemption from the registration requirements of said Act.
FAQ
What is the partnership between WISeKey and Digital Diagnostics AG about?
How quickly can the digid cantisense™ test provide results?
What is the revenue projection for WISeKey in the AIoT healthcare sector?
How does the digid cantisense™ test work?
What technology does WISeKey utilize in their partnership with Digital Diagnostics AG?
